Go to:
Top news
Purenum will operate as a subsidiary of FARCO-PHARMA and will continue to advance its work in the area of research & development.
GO-Bio initial
GO-Bio next
Selection panel GO-Bio initial
Selection panel GO-Bio next
FAQ GO-Bio initial
FAQ GO-Bio next
Successes of the GO-Bio programme
Talking about
Platform technology for enzymatic de novo DNA synthesis
News
Use of natural killer cells for cancer immunotherapy
Projects
Go-Bio initial Bootcamp
Endoprosthesis implantation
Gründungsgespräche
Synthetic biology against neurodegenerative diseases
